ADHD Therapeutics Market Size and Share|2030

[Research Report] The ADHD therapeutics market size was valued at US$ 28,594.55 million in 2022 and is expected to reach US$ 64,742.37 million by 2030; it is estimated to record a CAGR of 10.8% during 2022–2030. 

Market Insights and Analyst View:

Attention deficit/hyperactivity disorder (ADHD) is a complex neurodevelopment disorder that affects individuals’ ability to focus, control impulsive behaviors, and manage hyperactivity. It is mostly diagnosed in childhood, but symptoms can persist into adolescence and adulthood. Treatment for ADHD often involves a multidisciplinary approach, including behavioral therapy, education, and medication such as stimulants and non-stimulants.

Factors such as the growing prevalence of ADHD and a surge in the demand for treatment drugs propel the growth of the market. However, side effects associated with ADHD drugs and their limited relief impede the ADHD therapeutics market growth.

Growth Drivers and Restraints:

As per the article published by the Centers for Disease Control and Prevention (CDC), in February 2022, approximately 6 million children aged 3–17 years in the US were diagnosed with ADHD, accounting for 9.8% of the population between 2016 and 2019. Additionally, according to an article published by PubMed Central in 2022, ADHD affects 5–7.2% of children and 2.5–6.7% of adults worldwide. According to recent estimates, the frequency of adolescents in the US is much greater, at roughly 8.7% or 5.3 million. Although it has traditionally been thought of as a childhood condition, up to 90% of children with ADHD continue to have symptoms in adulthood. It is also possible to diagnose in adults because 75% of individuals with ADHD were not previously diagnosed during childhood, according to a research study. ADHD is frequently associated with comorbid conditions such as anxiety, depression, learning disorders, and substance abuse. The presence of these comorbidities increases the treatment complexity, necessitating a multi-dimensional approach that addresses both ADHD symptoms and associated conditions. Drugs such as psychostimulants and non-stimulants are recommended, which can assist children in managing their ADHD symptoms in their daily lives and can help regulate behaviors that may cause difficulties in various aspects of their lives, including personal life and academic performance. Thus, the factors mentioned above are increasing the demand for drugs indicated for ADHD, facilitating the expansion of the ADHD therapeutics market share.

However, the growth of the ADHD therapeutics market is restricted due to the limited relief of symptoms and the side effects associated with the use of therapeutics. Common side effects of psychostimulant medication include decreased appetite, insomnia, increased anxiety, increased irritability, stomach ache, and headache. When the effects of the medication wear off, ADHD symptoms may return, causing the "rebound" effect that can be more intense.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

ADHD Therapeutics Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Report Segmentation and Scope:

The “ADHD therapeutics market analysis” has been carried out by considering the following segments: drug type, age group, and distribution channel.

Segmental Analysis:

The ADHD therapeutics market, by drug type, is segmented into stimulants and non-stimulant drugs.

The stimulant drug segment held a larger ADHD therapeutics market share in 2022 and is anticipated to register a higher CAGR during 2022–2030.

ADHD Therapeutics Market by Drug Type – 2022 and 2030

Based on age group, the ADHD therapeutics market is segmented into pediatric & adolescent and adult. The pediatric & adolescent segment held a larger market share in 2022. The adult segment is anticipated to register a higher CAGR from 2022 to 2030.

In terms of distribution channel, the ADHD therapeutics market is categorized into hospital pharmacies, retail pharmacies, and E-commerce. In 2022, the hospital pharmacies segment held the largest market share and is anticipated to register the highest CAGR during 2022–2030.

Regional Analysis:

North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa are the major regions analyzed for deriving the ADHD therapeutics market report scope.

In 2022, North America held the largest global market share. In North America, the US held the largest share of the market in 2022 and is estimated to continue its dominance from 2022 to 2030. The ADHD therapeutics market growth is largely driven due to the high prevalence of ADHD in the US. According to Cingulate, ~6.4 million children and adolescents between 4 and 17 years of age were diagnosed with ADHD in 2022. Among them, over 80% of this group receive treatment, and about 65% experience ongoing symptoms of ADHD into adulthood. Additionally, improved patient affordability, favorable reimbursement policies, and increased awareness of current drugs are expected to drive market growth.

Asia Pacific is the fastest-growing market for ADHD owing to the presence of key players in the region and several strategic initiatives undertaken to develop and market new products. For example, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. reported positive results from its two six-week phase 3 clinical trials that assessed the effectiveness, safety, and tolerability of oral centanafadine. Centanafadine is a new experimental drug designed to treat adult patients diagnosed with ADHD. The company also planned to study the effects of centanafadine in children with ADHD and to discuss the next steps with the US Food and Drug Administration.

Industry Developments and Future Opportunities:

The ADHD therapeutics market forecast can help stakeholders in this marketplace plan their growth strategies. Initiatives taken by key players performing in the market are listed below:

1. In September 2023, Cingulate Inc. announced results from its Phase 3 study of adult efficacy and safety of its lead candidate, CTx-1301 (dexmethylphenidate), for treating ADHD. The company utilizes Precision Timed Release (PTR), its patented drug delivery platform technology, to build and advance a pipeline of next-generation pharmaceutical products. The results were presented on September 8th at the 36th Annual Psych Congress in Nashville, TN.
2. In March 2022, Noven Pharmaceuticals, Inc., a completely owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., got approval from the US Food and Drug Administration (FDA) for its XELSTRYM (dextroamphetamine) transdermal system, CII, for the treatment of ADHD in adults and pediatric patients aged six years and above.
3. In July 2021, Corium, Inc. launched AZSTARYS. This innovative medication combines Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) in the US for symptomatic treatment in patients aged 6 years and above. AZSTARYS got FDA approval in March 2021. It comprises a combination of two types of medication: 70% extended-release prodrug of d-MPH SDX (Schedule IV) and 30% immediate-release d-MPH (Schedule II).
4. In April 2021, Supernus Pharmaceuticals, Inc. announced that the US FDA had approved a Qelbree (viloxazine extended-release capsules) to treat ADHD in patients aged 6–17.

Competitive Landscape and Key Companies:

Amneal Pharmaceuticals, Inc.; Novartis AG; Pfizer, Inc.; Eli Lilly and Company; Noven Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Services, Inc.; Corium Inc; Adlon Therapeutics LP; and Teva Pharmaceutical Industries Ltd. are among the key players profiled in the ADHD therapeutics market report. These companies adopt product development strategies to meet growing customer demands, which allows them to maintain their brand name.

ADHD Therapeutics Report Scope